Methods of treatment or prevention of immune responses and inflammatory diseases with antagonistic CD40 monoclonal antibodies
US12419953B2 · kind B2 · utility
0Cited by
19References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2024 |
| Grant date | Sep 23, 2025 |
| Priority date | — |
| Expiry date | Feb 14, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/63
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.